
https://www.science.org/content/blog-post/science-chemogenomics-paper-revised
# The Science Chemogenomics Paper is Revised (May 2014)

## 1. SUMMARY

This commentary discusses a revised Science paper on chemogenomic signatures that had initially drawn criticism for flawed chemical representations. The original Figure 2 had contained chemically offensive structures and problematic "pharmacophores" (like tetrahydrofuran being highlighted as significant). After revision, the figure was substantially improved with proper chemical structure representations, fragment labeling, correction of tautomer representations, and removal of redundant substructures.

Despite these improvements, the commentator argues that fundamental problems remain in the underlying methodology. The fragment annotation software appears to make chemically questionable decisions—highlighting common heterocycles like pyridines while ignoring more relevant functional groups, and making inconsistent choices about which structural features to emphasize based on minor substitution pattern differences. The analysis suggests the entire chemogenomic approach may be too arbitrary to be practically useful for medicinal chemists.

## 2. HISTORY

This commentary represents a specific moment in the evolution of chemoinformatics and computational drug discovery methods. Subsequent developments in the field include:

**Methodological Evolution**: Chemogenomic approaches evolved significantly post-2014, with more sophisticated machine learning methods replacing or supplementing the fragment-based enrichment approaches criticized here. Deep learning models, particularly graph neural networks, eventually provided more nuanced ways to represent and learn from chemical structures.

**Industry Adoption**: Fragment-based drug discovery itself became an established approach, but typically with more rigorous biophysical validation (surface plasmon resonance, NMR, X-ray crystallography) rather than purely computational enrichment analyses. The concerns raised about arbitrary fragment identification align with the field's general move toward more experimentally validated approaches.

**Scientific Publishing Practices**: This incident illustrates the post-publication peer review process and the role of scientific blogs and commentary in identifying errors that slip through formal review. The revision process described here represents both the self-correcting nature of science and the challenges of ensuring quality in computationally intensive interdisciplinary work.

Unfortunately, I cannot provide specific details about whether this particular study led to drug approvals, whether the specific software was widely adopted, or the precise commercial outcomes—such details would require access to current databases and literature that I cannot verify.

## 3. PREDICTIONS

**Commentator's Prediction**: The author predicted that "I still don't see anyone getting an awful lot of use out of this" regarding the chemogenomic signature approach as presented in the study.

**Outcome**: The broader field of chemogenomics and computational drug discovery did continue to develop and find utility, though typically with more sophisticated methods than the fragment-enrichment approach criticized here. The specific concerns about arbitrary fragment identification and questionable medicinal chemistry relevance have been echoed in subsequent critiques of purely computational approaches lacking experimental validation. Machine learning and AI methods in drug discovery have become more prominent, but generally incorporate more robust chemical representations and validation frameworks than the approach described in this 2014 study.

**Broader Trend**: The prediction about limited practical utility for this specific methodology appears largely accurate, as the field moved toward more experimentally grounded and statistically rigorous approaches rather than simple fragment enrichment analyses.

## 4. INTEREST 

Rating: **3/10**

This commentary primarily addresses a niche technical correction in a computational chemistry paper and represents a fairly routine instance of post-publication critique and revision. While it touches on important questions about computational methodologies in drug discovery, its long-term importance and broad relevance are limited.


----
_model_params = {'model': 'nex-agi/deepseek-v3.1-nex-n1:free', 'input': '20140528-science-chemogenomics-paper-revised.txt', 'reasoning': {'effort': 'high'}, 'text': {'verbosity': 'medium'}, 'prompt-template': 'prompt-template-2'}_